Soluble recombinant αvβ3 adhesion receptor

US8067197B2 · kind B2 · utility

Assignee

• Merck Patent GmbH · DE

Inventors

• Simon Goodman
• Beate Diefenbach · Darmstadt, DE
• Detelv Güssow · London, GB
• Raj J. Mehta · Ambawadi, IN
• Eilish Cullen · London, GB
• Alex Brown · London, GB

Key dates

• Filing date: Jun 13, 2003
• Grant date: Nov 29, 2011
• Expiry date: Dec 1, 2026

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C12N2799/026
• WIPO field: Biotechnology
• WIPO sector: Chemistry

Abstract

The invention relates to a novel purified recombinant αVβ3 adhesion receptor which shows an unimpaired ligand binding activity, and a process for preparing said soluble non-membrane bound receptor in excellent yields by recombinant techniques using a baculovirus-insect cell expression system. The so-synthesized soluble receptor may be used very easily as screening tool for new therapeutic compounds which may inhibit the natural αVβ3 adhesion receptor. Such therapeutic compounds which can be discovered very easily, fast and without health risk by means of the soluble receptors according to the invention may be, for example, RGD peptides or non-peptidic compounds mimicking the natural ligand epitopes. The invention relates, furthermore, to a corresponding process for preparing recombinant full-length αVβ3 adhesion receptor in excellent yields, additionally using detergents to dissolve the membrane bound receptor from the surface of the host cell.